Spots Global Cancer Trial Database for chronic myeloid leukemia
Every month we try and update this database with for chronic myeloid leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients | NCT01275196 | Chronic Myeloid... | Nilotinib Imatinib | 18 Years - | Novartis | |
| CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey | NCT03647215 | Chronic Phase C... Accelerated Pha... Blastic Phase C... Philadelphia Ch... | 18 Years - | Incyte Corporation | ||
| TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study | NCT01657604 | Chronic Myeloid... | Peginterferon α... Nilotinib | 18 Years - | University of Jena | |
| Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01207440 | Chronic Myeloid... Ph+ Acute Lymph... | Ponatinib | 18 Years - | Takeda | |
| Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting | NCT01244750 | Chronic Myeloid... | 18 Years - | Bristol-Myers Squibb | ||
| Frontline Asciminib Combination in Chronic Phase CML | NCT03906292 | Chronic Myeloid... | Imatinib Nilotinib 300 m... Dasatinib Asciminib | 18 Years - | University of Jena | |
| Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor | NCT03907670 | Chronic Phase C... | 20 Years - 80 Years | Assiut University | ||
| Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia | NCT00852566 | Chronic Myeloid... | Imatinib Dasatinib | 18 Years - | Norwegian University of Science and Technology | |
| Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response | NCT04104035 | Chronic Myeloid... | 18 Years - | Ankara University | ||
| Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib | NCT01564836 | Chronic Myeloid... Imatinib Complete Molecu... | Imatinib treatm... | 18 Years - | Seoul St. Mary's Hospital | |
| Nilotinib in PH+, BCR-, ABL+ CML Patients | NCT01535391 | Chronic Myeloid... | Nilotinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | NCT04156256 | Hematologic Mal... Acute Myeloid L... Myelodysplastic... Myeloproliferat... Chronic Myeloid... | CD123-CD33 cCAR... | - | iCell Gene Therapeutics | |
| Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach | NCT03540654 | Hematologic Dis... Chronic Myeloid... | Budget impact | 18 Years - | University Hospital, Bordeaux | |
| A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib | NCT01215487 | Chronic Myeloid... | Stem Cell and M... | 18 Years - | University of British Columbia | |
| Nilotinib Pre and Post Allogeneic Stem Cell Transplantation | NCT00750659 | Chronic Myeloid... Acute Lymphobla... Stem Cell Trans... | Nilotinib | 18 Years - 65 Years | Sheba Medical Center | |
| Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) | NCT00827138 | Chronic Myeloid... | DCC-2036 | 18 Years - | Deciphera Pharmaceuticals LLC | |
| Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy | NCT02487069 | Acute Leukemia Chronic Myeloid... Myelodysplastic... | HSCT from MSD HSCT from MUD HSCT from HRD Cyclosporin A Methotrexate Antithymocyte g... Mycophenolate m... | 18 Years - 60 Years | Nanfang Hospital, Southern Medical University | |
| Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers | NCT00488592 | Myelodysplastic... Acute Myeloid L... Chronic Myeloid... | WT1:126-134 PR1:169-177 Pep... GM-CSF (Sargram... Montanide adjuv... | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) | NCT01392170 | Leukemia | PEG-IFNá-2a | 16 Years - | M.D. Anderson Cancer Center | |
| Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia | NCT02709083 | Chronic Myeloge... Chronic Myeloid... Leukemia | Dasatinib Imatinib Mesyla... Nilotinib | 17 Years - | Emory University | |
| A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I) | NCT01751919 | Chronic Myeloid... Gastrointestina... | Imatinib mesyla... Glivec film-coa... | 20 Years - 50 Years | Dong-A ST Co., Ltd. | |
| Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT00519090 | Myelogenous Leu... | Imatinib Nilotinib (AMN1... | 18 Years - | Novartis | |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia | NCT06163430 | Chronic Myeloid... Chronic Myeloid... | TERN-701 | 18 Years - | Terns, Inc. | |
| A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) | NCT01077544 | Chronic Myeloid... Acute Lymphobla... | Nilotinib | 1 Year - 17 Years | Novartis | |
| Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia | NCT01768689 | Leukemia, Myelo... Medication Adhe... | Adherence-encou... Adherence-encou... Adherence-encou... | 18 Years - | Rabin Medical Center | |
| Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies | NCT01622556 | Hematologic Mal... | Fludarabine Busulfan Thymoglobulin Total Body Irra... Umbilical Cord ... | 18 Years - 70 Years | University of Virginia | |
| Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients | NCT01169753 | Chronic Myeloid... | Placebo Armodafinil | 18 Years - | M.D. Anderson Cancer Center | |
| Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) | NCT00038805 | Leukemia | Mylotarg | 55 Years - 75 Years | M.D. Anderson Cancer Center | |
| A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting | NCT04089839 | Chronic Myeloid... | Non-Interventio... | 18 Years - | Bristol-Myers Squibb | |
| Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients | NCT00386373 | Leukemia | Imatinib Mesyla... | 16 Years - | M.D. Anderson Cancer Center | |
| Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity | NCT02016833 | Ovarian Serous ... Undifferentiate... Cervical Cancer Cervical Intrae... Acute Myeloid L... Chronic Myeloid... | Blood Sampling | 18 Years - 70 Years | PX Biosolutions | |
| Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia | NCT00162513 | Chronic Myeloid... | Allogeneic tumo... | 55 Years - | Hadassah Medical Organization | |
| Treatment Free Remission (TFR) in CML Patients （CML-CP）Study | NCT05440747 | Chronic Myeloid... Treatment-free ... | TFR(Treatment-F... | 14 Years - | Guangdong Provincial People's Hospital | |
| Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial | NCT01627132 | Chronic Myeloid... | Dasatinib | 15 Years - | Shimousa Hematology Study Group | |
| Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis | NCT06042660 | Chronic Myeloid... | the prevalence ... | 18 Years - | Polish Adult Leukemia Group | |
| Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia | NCT00352677 | Chronic Myeloid... Acute Lymphocyt... | INNO-406 | 18 Years - | CytRx | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia | NCT03348033 | Chronic Myeloid... | Chronic Myeloid... | 2 Years - 59 Years | Hospital de Clinicas de Porto Alegre | |
| The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans | NCT04126707 | Chronic Myeloid... | [14C] HQP1351 | 18 Years - 50 Years | Ascentage Pharma Group Inc. | |
| Study Conducted Among Patients With CML | NCT05476562 | Chronic Myeloid... | Tyrosine Kinase... | 18 Years - 85 Years | Novartis | |
| Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy | NCT00896129 | Chronic Myeloid... | HRQOL Survey Pa... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation | NCT01068301 | Acute Lymphobla... Acute Myeloid L... Chronic Myeloid... Myelodysplastic... Non-Hodgkin's L... | Plerixafor | - 21 Years | St. Jude Children's Research Hospital | |
| Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation | NCT00375219 | Chronic Myeloid... | Omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence | NCT04663100 | Chronic Myeloid... Chronic Lymphoc... Multiple Myelom... Multiple Chroni... | Patient-reporte... Comprehensive M... Pharmacist comm... | 18 Years - | University of Tennessee | |
| Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib | NCT00461929 | Chronic Myeloid... Gastrointestina... Chromosome Abno... | bone marrow asp... | 18 Years - | University Health Network, Toronto | |
| Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib | NCT02398825 | Chronic Myeloid... Chronic Phase Adults | Ponatinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | NCT04464889 | Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Myeloproliferat... Chronic Myeloid... Myelofibrosis Multiple Myelom... Malignant Lymph... | MDG1021 dose 1 MDG1021 dose 2 MDG1021 dose 3 MDG1021 optimal... | 18 Years - | Medigene AG | |
| Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment | NCT05387330 | Chronic Myeloid... | ELISA kit | 18 Years - | Tanta University | |
| Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | NCT00333840 | Chronic Myeloge... | imatinib mesila... interferon-alph... cytarabine (ARA... | 18 Years - 70 Years | Novartis | |
| TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study | NCT01657604 | Chronic Myeloid... | Peginterferon α... Nilotinib | 18 Years - | University of Jena | |
| Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | NCT00522990 | Acute Myeloid L... Acute Lymphobla... Chronic Myeloid... Myelodysplastic... Myelofibrosis | AT9283 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene | NCT00710892 | Acute Lymphobla... Non-Hodgkin's L... Myelodysplastic... Chronic Myeloid... | Allodepleted T ... | - 65 Years | Baylor College of Medicine | |
| KRT-232 and TKI Study in Chronic Myeloid Leukemia | NCT04835584 | Chronic Myeloid... | KRT-232 Dasatinib Nilotinib | 18 Years - | Kartos Therapeutics, Inc. | |
| Venetoclax After TKI to Target Persisting Stem Cells in CML | NCT05701215 | Chronic Myeloid... | Venetoclax | 18 Years - | University of Jena | |
| Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00152139 | Acute Lymphobla... Acute Myelocyti... Chronic Myeloid... Juvenile Myelom... Myelodysplastic... Hemoglobinuria,... Non-Hodgkin Lym... | Allogeneic Stem... Chemotherapy an... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies | NCT02352558 | Hematologic Mal... | BBI608 Dexamethasone Bortezomib Imatinib Ibrutinib | 18 Years - | Sumitomo Pharma America, Inc. | |
| Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients | NCT02253277 | Chronic Myeloid... | Nilotinib Ruxolitinib | 18 Years - | Novartis | |
| Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia | NCT03228303 | Chronic Myeloid... | Nilotinib 150 M... Imatinib 400mg | 18 Years - | Assiut University | |
| CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia | NCT06163430 | Chronic Myeloid... Chronic Myeloid... | TERN-701 | 18 Years - | Terns, Inc. | |
| Cancer Experience Registry (CER) for Cancer Patients and Caregivers | NCT02333604 | Neoplasms Cancer Caregiver | 18 Years - | Cancer Support Community, Research and Training Institute, Philadelphia | ||
| Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT00101595 | Chronic Myeloid... Leukemia, Lymph... | Dasatinib | 18 Years - | Bristol-Myers Squibb | |
| Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) | NCT01570868 | Leukemia | Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients | NCT02201459 | Chronic Myeloid... | Nilotinib (Tasi... Nilotinib (Tasi... | 18 Years - 65 Years | Hospices Civils de Lyon | |
| Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy | NCT03880617 | CML GIST | - | National Taiwan University Hospital | ||
| Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality | NCT03746054 | Chronic Myeloid... | Optimal medical... usual clinical ... | 18 Years - | University Hospital, Angers | |
| Pasireotide in Prevention of GI Toxicity | NCT02215070 | Hematological M... | Pasireotide | 18 Years - | Duke University | |
| CML Pediatric ITK Response According to Molecular Identification at Diagnosis | NCT05605379 | Chronic Myeloid... | Next Generation... | 6 Years - 18 Years | University Hospital, Bordeaux | |
| Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | NCT00038675 | Chronic Myelomo... Chronic Myeloid... Polycythemia Ve... Hypereosinophil... Mastocytosis | Imatinib Mesyla... | - | M.D. Anderson Cancer Center | |
| Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia | NCT03075969 | Chronic Myeloid... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | ||
| Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium | NCT03678454 | Chronic Myeloid... CML Philadelphia Ch... Ph+ ALL | 18 Years - | Incyte Corporation | ||
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) | NCT01392170 | Leukemia | PEG-IFNá-2a | 16 Years - | M.D. Anderson Cancer Center | |
| Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT01019317 | Leukemia AML MDS CML | Cytarabine Fludarabine | 12 Years - | M.D. Anderson Cancer Center | |
| Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients | NCT01578213 | Chronic Myeloid... | Imatinib mesyla... | 18 Years - | University of Milano Bicocca | |
| Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib | NCT00461929 | Chronic Myeloid... Gastrointestina... Chromosome Abno... | bone marrow asp... | 18 Years - | University Health Network, Toronto | |
| Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML | NCT01690065 | Chronic Myeloid... Untreated Adult... | Nilotinib+AD in... | 18 Years - 65 Years | Ulsan University Hospital | |
| A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation | NCT01068301 | Acute Lymphobla... Acute Myeloid L... Chronic Myeloid... Myelodysplastic... Non-Hodgkin's L... | Plerixafor | - 21 Years | St. Jude Children's Research Hospital | |
| Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib | NCT02398825 | Chronic Myeloid... Chronic Phase Adults | Ponatinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia | NCT03228303 | Chronic Myeloid... | Nilotinib 150 M... Imatinib 400mg | 18 Years - | Assiut University | |
| Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00152139 | Acute Lymphobla... Acute Myelocyti... Chronic Myeloid... Juvenile Myelom... Myelodysplastic... Hemoglobinuria,... Non-Hodgkin Lym... | Allogeneic Stem... Chemotherapy an... | 2 Years - 21 Years | St. Jude Children's Research Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
